Compare WKHS & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | MAIA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 79.0M |
| IPO Year | 2008 | 2022 |
| Metric | WKHS | MAIA |
|---|---|---|
| Price | $3.03 | $1.34 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | 97.8K | ★ 539.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.92 | 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $763,173.00 | N/A |
| Revenue This Year | $89.23 | N/A |
| Revenue Next Year | $28.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.87 |
| 52 Week High | $11.80 | $3.19 |
| Indicator | WKHS | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 46.30 |
| Support Level | $2.89 | $1.25 |
| Resistance Level | $3.56 | $1.48 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 22.34 | 26.32 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.